{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:libtayo:0:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Alibtayo%3A0%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002137, "timestamp_received": "2026-10-16T22:58:06.413718+00:00Z", "timestamp_returned": "2026-10-16T22:58:06.415855+00:00Z", "trace_id": "aaae72a3-55f8-428e-8ab5-2a59b3ec8b63" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:libtayo:0:0", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2021-06-21:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2021-06-21", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:libtayo", "type": "Document", "documentType": "Regulatory approval", "name": "Libtayo (cemiplimab) [product information]. EMA.", "title": null, "aliases": [], "description": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Regeneron Ireland Designated Activity Company (DAC).", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Libtayo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "cemiplimab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2019-07-05", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-01-12", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:618", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C2926", "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Non-Small+Cell+Lung+Cancer+%28NSCLC%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C2926", "code": "C2926", "name": "Lung Non-Small Cell Carcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2926" ] } }, "objectTherapeutic": { "id": "tx:ncit:C121540", "conceptType": "Therapy", "name": "Cemiplimab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2058826", "code": "2058826", "name": "cemiplimab", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2058826" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:35200783", "code": "35200783", "name": "cemiplimab", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/35200783" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "PD-1/PD-L1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C121540", "code": "C121540", "name": "Cemiplimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121540" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:39", "present": true, "subject": { "id": "bmkr:39", "type": "CategoricalVariant", "name": "PD-L1 >= 50%", "constraints": [], "extensions": [ { "name": "biomarker_type", "value": "Protein expression" }, { "name": "marker", "value": "PD-L1" }, { "name": "unit", "value": "Tumor Proportion Score (TPS)" }, { "name": "equality", "value": ">=" }, { "name": "value", "value": 0.5 } ] } }, { "id": "bmkr.criterion:34", "present": true, "subject": { "id": "bmkr:34", "type": "CategoricalVariant", "name": "Wild type ALK", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_004295.2, the protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5).", "digest": "o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ", "sequenceReference": { "id": "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "type": "SequenceReference", "name": "NP_004295.2", "aliases": [ "ensembl:ENSP00000373700.3", "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "refseq:NP_004295.2" ], "description": "The protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5), corresponding to the Refseq protein accession NP_004295.2.", "moleculeType": "protein", "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs", "residueAlphabet": "aa" }, "start": 0, "end": 1620, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:427", "conceptType": "Gene", "name": "ALK", "primaryCoding": { "id": "coding:hgnc:427", "code": "HGNC:427", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000171094", "code": "ENSG00000171094", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000171094" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:238", "code": "238", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/238" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004304.5", "code": "NM_004304.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } }, { "id": "bmkr.criterion:35", "present": true, "subject": { "id": "bmkr:35", "type": "CategoricalVariant", "name": "Wild type EGFR", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5).", "digest": "gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt", "sequenceReference": { "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "type": "SequenceReference", "name": "NP_005219.2", "aliases": [ "ensembl:ENSP00000275493.2", "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "refseq:NP_005219.2" ], "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.", "moleculeType": "protein", "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE", "residueAlphabet": "aa" }, "start": 0, "end": 1210, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:3236", "conceptType": "Gene", "name": "EGFR", "primaryCoding": { "id": "coding:hgnc:3236", "code": "HGNC:3236", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000146648", "code": "ENSG00000146648", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000146648" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:1956", "code": "1956", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/1956" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005228.5", "code": "NM_005228.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } }, { "id": "bmkr.criterion:46", "present": true, "subject": { "id": "bmkr:46", "type": "CategoricalVariant", "name": "Wild type ROS1", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.hC1t5wa3TfUMtSYa_g0a5hP5qipSxyku", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_001365831.1, the protein product of the MANE Select coding transcript for ROS1 (refseq:NM_001378902.1).", "digest": "hC1t5wa3TfUMtSYa_g0a5hP5qipSxyku", "sequenceReference": { "id": "ga4gh:SQ.22Sf5cMxU4cVHRP44TPGjT-lO17K4Dfc", "type": "SequenceReference", "name": "NP_001365831.1", "aliases": [ "ensembl:ENSP00000357493.3", "ga4gh:SQ.22Sf5cMxU4cVHRP44TPGjT-lO17K4Dfc", "refseq:NP_001365831.1" ], "description": "The protein product of the MANE Select coding transcript for ROS1 (refseq:NM_001378902.1), corresponding to the Refseq protein accession NP_001365831.1.", "moleculeType": "protein", "refgetAccession": "SQ.22Sf5cMxU4cVHRP44TPGjT-lO17K4Dfc", "residueAlphabet": "aa" }, "start": 0, "end": 2341, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:10261", "conceptType": "Gene", "name": "ROS1", "primaryCoding": { "id": "coding:hgnc:10261", "code": "HGNC:10261", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000047936", "code": "ENSG00000047936", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000047936" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:6098", "code": "6098", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/6098" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_001378902.1", "code": "NM_001378902.1", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:libtayo:0", "type": "Indication", "description": "LIBTAYO as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:ema:2021-06-21:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2021-06-21", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } } ], "reportedIn": [ { "id": "doc:ema:libtayo", "type": "Document", "documentType": "Regulatory approval", "name": "Libtayo (cemiplimab) [product information]. EMA.", "title": null, "aliases": [], "description": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Regeneron Ireland Designated Activity Company (DAC).", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Libtayo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "cemiplimab", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2019-07-05", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-01-12", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }